These results show i) 1% of auto-correlations variability is sufficient to discriminate different genotypes, and ii) the similar global gene expression behavior between single KOs and DKO suggests DKO possesses LPS response, too (see also section 'Emergence of regulatory signature from scattered expressions in all genotypes' for further proof of DKO response).
While this clinical success demonstrates proof-of-principle, the clinical response is limited to a subset of patients.
Efficacy endpoints of this proof-of-concept study included response rate, time to first metastasis, progression-free and overall survival (OS).
Although future studies will be necessary to improve strength and breadth of the elicited neutralizing response, this proof-of-concept study documents that immunogens designed on the idiotype of broadly neutralizing Abs are feasible and could help in the design of future anti-HIV strategies.
Pre-defined efficacy endpoints for this proof-of-concept study included objective response rate, time to first metastasis, progression-free survival (PFS) and overall survival (OS).
Although piglets are recognized as an ideal model for human infant neuroscience research due to their similarity in size, brain development, physiology, and pathophysiologic responses, our proof-of-concept study indicates that the piglet is a suitable model for anesthetic neurotoxicity screening [31, 32].
The relatively slow time response of the proof-of-concept device can be readily improved by integrating on-chip heaters, while the latchability of the microvalve can be improved by optimizing the wax chamber and membrane design.
To test the idea of employing marker tolerant animals as a model for regenerative therapies, we initially used lethal irradiation and transplantation of bone marrow from hPLAP-tg F344 rats into wild-type F344 rats as proof-of-principle to prevent the immune response after injection of transgenic cells into wild-type rats.
Furthermore, our results continue to show that Ki-67 expression is associated with the risk biomarker cytomorphology in high-risk women, and thus they provide evidence that Ki-67 may be used as a response biomarker in proof-of-principle phase II trials.
As the search continues for new HIV vaccine strategies capable of inducing systemic and mucosal immune responses, the present proof-of-principle study suggests that live CVB4/HIV recombinants are worth exploring as new vaccine candidates.
